Comments
Commented by Armin Schulz on September 22nd, 2025 | 07:00 CEST
Your gold playbook: Profit from rising prices with Barrick Mining, Dryden Gold, and Newmont
Gold is experiencing a spectacular rally, driven by interest rate cuts from the US Federal Reserve and an uncertain economic outlook. As a safe haven, the precious metal is benefiting directly from this monetary policy shift, which is lowering opportunity costs for investors and fueling demand as a hedge against inflation. This ideal setup could help stabilize the price at a high level and offers attractive opportunities. Against this backdrop, it is worth taking a look at the strategies of Barrick Mining, Dryden Gold and Newmont.
Read
Commented by Fabian Lorenz on September 19th, 2025 | 07:10 CEST
+19% in one day! SHORT SQUEEZE at D-Wave Quantum? What is going on with TeamViewer? STOCK MARKET NEWCOMER Finexity enters the billion-dollar market!
D-Wave Quantum's stock exploded by 19% on Wednesday and held up well yesterday. Is this the start of a short squeeze? We had only just pointed out the high short ratio on Tuesday. Now, the Company has reached a new all-time high and has gained over 2,100% in just 12 months. Finexity shareholders would likely love to see a similar performance. But one step at a time. First, the newcomer has to establish itself on the stock market. Investors now have a chance to get in early on an exciting business model. Meanwhile, does TeamViewer offer a buying opportunity after its 30% drop? Technically, the stock is in bad shape, but operationally, the German technology company is performing better than the chart suggests.
Read
Commented by Armin Schulz on September 19th, 2025 | 07:05 CEST
BYD expands, Pasinex Resources acquires, Puma attracts buyers: How you can profit from the latest news
While global markets are in flux, two companies are pursuing proactive strategies for future growth. An e-mobility pioneer is skillfully circumventing trade barriers by expanding local production. A mining explorer is securing control of valuable resources through a complete takeover. At the same time, a major sportswear brand has become a takeover target itself, facing increased speculation. The strategic moves by BYD and Pasinex Resources, as well as the ongoing debate about Puma's future, offer key insights for investors. We take a closer look at where to invest right now.
Read
Commented by Fabian Lorenz on September 19th, 2025 | 07:00 CEST
Buy Nordex shares? RENK is betting on vehicle manufacturing! Is Graphano Energy too cheap?
No battery works without graphite. At the same time, the raw material is scarce and geopolitically sensitive. This benefits Graphano Energy. Is the stock undervalued? The Company is facing important months ahead. RENK shares are not cheap. But the supercycle in the defense industry is expected to generate strong profits over the coming decade. To handle the anticipated flood of orders, RENK is relying on production standards from the automotive industry. And what about Nordex? Investors are concerned about political headwinds. But analysts are offering reassurance and recommend buying the stock.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST
Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!
Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.
Read
Commented by André Will-Laudien on September 18th, 2025 | 07:20 CEST
Margins war and soaring commodity prices! Caution advised on BYD, Mercedes, RENK, and European Lithium
So far, September has turned out to be a month of bliss. It appears that the stock market already underwent its full correction back in April. Investors are still buying high-tech and AI stocks, seemingly unconcerned by valuations of historic proportions. In the wake of this super bull market, automakers BYD and Mercedes have recently suffered significant price corrections. At the same time, the wave of euphoria surrounding defense stock RENK now appears somewhat exaggerated. The rally around critical metals has also driven European Lithium and its US subsidiary Critical Metals significantly higher. With commodity prices recently exploding, however, the rally here is likely only just beginning. We take a closer look at the numbers.
Read
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:10 CEST
MAJOR DEVELOPMENTS for megatrend stocks: Rheinmetall, BioNTech, First Hydrogen
Rheinmetall is going full throttle: on land, at sea, in the air, and even in space. Its latest bombshell is the announced takeover of Lürssen's naval division. Will this provide the tailwind the stock needs to break through the EUR 2,000 mark on a sustained basis? Analysts view the transaction positively, though some cautionary voices remain. Meanwhile, a major development in Canada is boosting sentiment around First Hydrogen. North Americans aim to be at the forefront of the small modular reactors (SMRs) movement. The potential is enormous. BioNTech also holds significant promise in the fight against cancer. However, challenges have emerged - ironically in the world's largest pharma market. The US government plans to cut or even stop funding for new mRNA vaccine development. BioNTech shares reacted accordingly and may break through their sideways trend downwards.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Carsten Mainitz on September 18th, 2025 | 07:00 CEST
Almonty Industries, thyssenkrupp, Nordex – Perfect news!
Rare earths and critical raw materials play a vital role across many sectors of the economy. They are essential for electric motors, permanent magnets, and battery technologies and are of great importance in the defense industry. China controls the majority of global reserves and is restricting exports. Western countries have long been making great efforts to secure deposits outside China, with particular pressure coming from the US. A recently published report by Bloomberg has raised eyebrows.
Read